《2017 Human Coronavirus Circulation in the USA, 2014_2017》由会员分享，可在线阅读，更多相关《2017 Human Coronavirus Circulation in the USA, 2014_2017（2页珍藏版）》请在金锄头文库上搜索。
1、Poster Abstracts OFID 2017:4 (Suppl 1) S311 9). Nasal specimens were used to detect clinical and colonizing pathogens using the Diatherix TEM-PCR RespiratoryPanel. Results. A total of 90 recruits were enrolled in the study. Twelve recruits were lost due to training attrition in the first week of the
2、 study. The participants were male and the mean age was 23 yo (SD 4.9). There were 10 (13%) cases of ILI reported among the 78 remaining participants, 6 in week 1, 3 in week 2 and 1 in week 9.The most frequently detected pathogens in the 10 symptomatic cases were coronavirus (5, 50%), rhinovirus (4,
3、 40%), other enterovirus (3, 30%), and influenza A(2, 20%). Pathogen co-detections were common, 8 out 10 cases were associated with 2 pathogens, repre- senting 7 unique combinations. While rhinovirus and coronavirus were most common among asymptomatic trainees, 10% had detectable influenza A.Detecti
4、on of multiple pathogens was common in the first two weeks of training (50% among those who had viral detection). The study is still in progress. Conclusion. Symptomatic ILI was associated with coronavirus, rhinovirus, and enterovirus, in addition to influenza in the early weeks of training. Coronav
5、irus and rhinovirus also circulated widely among healthy recruits, along with influenza. The findings will inform ILI control strategies for congregated military trainees. Disclosures. E. Grigorenko, Diatherix Laboratories: Employee, Salary.L. Malone, Diatherix Laboratories: Employee, Salary. 1028.
6、Pharmacokinetics (PK) and Safety of Intravenous (IV) Brincidofovir (BCV) in Healthy Adult Subjects Mary BethWire, PharmD; MarionMorrison, MD; MaggieAnderson, BS; ThangamArumugham, PhD; JohnDunn, PhD and OdinNaderer, PharmD; Chimerix, Durham, North Carolina Session: 139. Adult Viral Infection Friday,
7、 October 6, 2017: 12:30 PM Background. BCV is a lipid conjugate nucleotide that has shown rapid viral clear- ance in patients with adenovirus infection and improved survival in animal models of smallpox. In preclinical studies in rats, IV BCV dosed twice weekly for up to 29days was not associated wi
8、th gastrointestinal (GI), hematopoietic, hepatic, or renal toxicity. This study evaluated the safety and PK of IV BCV in healthy subjects. Methods. In this double-blind study, subjects were randomized 3:1 to receive IV BCV or placebo in sequential single ascending dose cohorts (Table1). Plasma PK sa
9、mples were collected over 7days and assayed by HPLC-MS. Plasma BCV PK param- eters were determined by non-compartmental analysis and dose proportionality was assessed. Safety assessments were collected over 14days. Results. Forty healthy male subjects (1846years, 83% White) were enrolled and complet
10、ed the study. Plasma BCV Cmax and AUC increased in proportion to dose (Table1). AEs and alanine aminotransferase (ALT) elevations were dose- and infusion duration-related (Table1). GI AEs were mild. All AEs and ALT elevations were tran- sient and no serious AEs occurred. Table1. IV BCV PK and Safety
11、 BCV 10mg 2h Infusion (n = 6) BCV 25mg 2h Infusion (n = 6) BCV 50mg 2h Infusion (n = 9) BCV 50mg 4h Infusion (n = 9) Pooled Placebo (n = 10) Plasma BCV PK Cmax (ng/ mL) 613 (25%)1412 (27%)2952 (19%)1586 (14%)NA AUC (ng h/ mL) 1312 (26%)2889 (37%)5948 (19%)6570 (15%)NA Drug-related AEs Diarrhea001 (1
12、1%)3 (33%)0 Nausea0002 (22%)0 Decreased appetite 0001 (11%) Headache002 (22%)2 (22%)0 Pain, phlebitis at infusion site 001 (11%)00 Elevated liver transami- nasesa 0001 (11%)0 Cmax and AUC presented as geometric mean (%CVb). aALT 2x ULN in 2 BCV 50mg 4h infusion and 1 placebo subjects; 1 ALT elevatio
13、n considered an AE. Conclusion. Single doses of BCV 1050mg administered as a 2h IV infusion were well tolerated and not associated with significant clinical or laboratory abnormal- ities. BCV IV 10mg and BCV IV 50mg achieved geometric mean plasma BCV AUC similar to and 4.5-fold, respectively, values
14、 achieved with BCV oral 100mg tablets (Cmax=251ng/mL and AUC=1394ng hours/mL). These data support evaluation of repeat dose administration in healthy subjects and virally-infected patients. Disclosures. M. B. Wire, Chimerix: Employee and Shareholder, Salary. M. Morrison, Chimerix: Employee and Share
15、holder, Salary.M. Anderson, Chimerix: Employee and Shareholder, Salary. T. Arumugham, Chimerix: Employee and Shareholder, Salary. J. Dunn, Chimerix: Employee and Shareholder, Salary. O. Naderer, Chimerix: Employee and Shareholder, Salary. 1029. AMortality Analysis of the Cytomegalovirus (CMV) Infect
16、ion Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT) JohanMaertens, M.D, PhD1; MichaelSchmitt, MD2; Francisco M.Marty, MD, FIDSA3; PerLjungman, MD, PhD4; Roy F.Chemaly, MD, MPH, FIDSA, FACP5; Nicholas A.Kartsonis, MD6; JoanButterton, MD6; HongWan, PhD6; Valerie L.Teal, M.S.6; KendraSarratt, PhD6; YoshihikoMurata, MD, PhD6; Randi Y.Leavitt, MD, PhD6 and CyrusBadshah, MD, PhD6; 1Universitaire Ziekenhuizen Leuven, Leuven, Belg
